Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 8INDUSTRY 3NIH 2NETWORK 1

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Gynecologic 3

Conditions

Ovarian Neoplasms 3

Interventions

Paclitaxel 490Carboplatin 436Gemcitabine 394Docetaxel 385Cisplatin 360pembrolizumab 344Bevacizumab 335Nivolumab 261Pemetrexed 243Capecitabine 221Dexamethasone 213Fluorouracil 211Rituximab 203Trastuzumab 193Cyclophosphamide 190Oxaliplatin 160Erlotinib Hydrochloride 147Ipilimumab 145atezolizumab 144Prednisone 144Cetuximab 142Irinotecan 139Leucovorin 130Doxorubicin 130Sorafenib 120Lenalidomide 119Bortezomib 118Sunitinib 107Everolimus 93130-nm albumin-bound paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × INDUSTRY × Laparotomy × Clear all
NCT02317705 2022-06-21

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 2 Completed
48 enrolled 10 charts
Gynecologic

Ovarian Neoplasms

NCT03180307 2022-02-04

OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

On Target Laboratories, LLC

Phase 3 Completed
140 enrolled 11 charts 1 FDA
Gynecologic

Ovarian Neoplasms

NCT02785731 2018-11-09

Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.

Angle plc

Completed
204 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡